CALL/VERTEX PHARMACEUTICALS/350/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 02:25:56 2024-05-31 pm EDT | ||
| 9.33 EUR | +10.28% |
|
| Current month | +94.38% | ||
| 1 month | +94.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 9.33 | +10.28% |
| 24-05-30 | 8.46 | -4.84% |
| 24-05-29 | 8.89 | -5.22% |
| 24-05-28 | 9.38 | -9.46% |
| 24-05-27 | 10.36 | +4.12% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 02:25 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP0BR4 |
| ISIN | DE000GP0BR40 |
| Date issued | 2023-03-08 |
| Strike | 350 $ |
| Maturity | 2024-06-21 (20 Days) |
| Parity | 10 : 1 |
| Emission price | 1.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.36 € |
|---|---|
| Lowest since issue | 2.44 € |
| Spread | 0.3 € |
| Spread % | 2.97% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
